In stable MS patients, stopping Ocrevus does not seem to increase the risk of disease activity or disability progression for ...

Managing risk is part of everyday business. But how do you deal with fear? Fear management has been a key challenge at Biogen Idec for the past four years, since a few patients taking the company’s ...

This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.

A University of Toronto-led study has identified a possible biomarker linked to multiple sclerosis (MS) disease progression. The findings, validated in both mouse and in humans, could help to identify ...

Swiss pharmaceuticals powerhouse Roche announced on Saturday that the company’s experimental multiple sclerosis drug met its primary goal in a late-stage trial in patients with a rare form of the ...

Add Yahoo as a preferred source to see more of our stories on Google. The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File ...

The National Institute for Health and Care Excellence (NICE) has recommended natalizumab for treating adults with highly active relapsing-remitting multiple sclerosis (RRMS) whose disease has ...